Arvinas ARV-471 Phase 3 primary endpoint met in HR+ breast cancer
VERITAC-2 topline: statistically significant PFS improvement vs. fulvestrant. First oral PROTAC to hit Phase 3.
Firehose
Feeds
Every update flowing through the platform — filter by source, entity type, or recency.
All signals
22 itemsIsomorphic Labs announces first IND-enabling study for AI-designed oncology candidate
Structure-based design via AlphaFold3 + proprietary generative chemistry. Target undisclosed.
Boltz-2 v0.4 release — 18% accuracy gain on PoseBusters benchmark
Improved affinity head, new confidence calibration. Inference latency unchanged. Drop-in replacement for v0.3.
RFdiffusion-AA paper published — all-atom de novo protein binder design
Baker lab. Atomic-accuracy binder generation against small-molecule targets. Benchmarks vs. AlphaProteo.
Recursion REC-994 Phase 2 interim: dose-response trend, safety profile clean
Cerebral cavernous malformation, 60-patient readout. Data support Phase 3 planning for H2 2026.
“The new Chai-1 benchmarks are more honest than anything I’ve seen from a foundation model team this year.”
Keynote recap: “AI drug discovery is entering the design phase, not the prediction phase.”
Ep. 84 — “Why generative antibody design is about to replace phage display”
Full schedule released — 16 papers on structure-based generative models
Insilico signs multi-target AI drug discovery deal with Menarini Group
Moderna Q1 pipeline update — 5 new oncology candidates advanced
Review: 8 open-source ADMET models benchmarked on TDC leaderboard
Schrödinger reports Q1 platform revenue up 18% on AI-driven licensing deals
AlphaProteo: benchmarks show 47% binding-affinity gain over RFdiffusion on viral targets
Six-target head-to-head. Binders tested via BLI + yeast display.